Understanding Signaling by Non-Canonical Receptor Tyrosine Kinases
Understanding Signaling by Non-Canonical Receptor Tyrosine Kinases
批准号:
9914306
负责人:
Mark A Lemmon
金额:
$80.34万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-05-01 至 2022-04-30
关键词:
AcylationBindingBinding ProteinsBiochemicalBiologyBone DiseasesCharacteristicsChemicalsComplexCongenital AbnormalityDefectDiabetes MellitusDiseaseFamilyGoalsGrowth FactorHumanKnowledgeLigandsMalignant NeoplasmsMethodsMolecular ConformationMutateNeurodevelopmental DisorderPhosphotransferasesPlayReceptor ActivationReceptor Protein-Tyrosine KinasesReceptor SignalingResearchResearch Project SummariesResolutionRoleSignal TransductionSignaling MoleculeSpecificityStructureTestingTherapeuticTyrosineWNT Signaling PathwayWnt proteinsdimerhuman diseasein vivoinsightmembernovel therapeutic interventionnovel therapeuticsreceptorreceptor bindingrecruittherapeutic targetwound healing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
The research proposed in this MIRA application seeks to understand unexplored mechanisms of
transmembrane signaling across the receptor tyrosine kinase (RTK) superfamily, members of which play an
important role in human disease – from neurodevelopmental disorders, to bone diseases, cancers, diabetes,
and several congenital malformations. In the traditional view of RTK signaling, growth factor ligands induce
receptor dimers that become tyrosine autophosphorylated and recruit downstream signaling molecules. As we
understand more about the 20 different RTK families (which include 58 RTKs), however, it becomes clearer
that this view only applies to a subset of these receptors. The research proposed here focuses on two
characteristics that demand a very different mechanistic view – RTKs that bind Wnt proteins (and do not
dimerize as a result) and RTKs that have `dead' kinase or pseudokinases in their intracellular regions. New
paradigms must be understood in order to appreciate how these important receptors signal. Our goals over
the next 5-10 years are: 1. To develop a coherent picture of the role played by RTKs in Wnt signaling (which
involves 4 of the 20 RTK families), 2. To understand how RTKs with pseudokinase domains that do not even
bind ATP (found in 5 of the 20 RTK families) can signal, and 3. To determine why pseudokinases are over-
represented among the Wnt-regulated RTKs. Guided by cellular and in vivo studies of receptor/ligand
relationships we will study ligand-induced complexes biochemically, and with high-resolution structural
approaches, in order to understand in detail how Wnt protein binding leads to activation of the receptors and
co-receptors in the signaling complex. In pursuing these studies, we will investigate the role played by Wnt
acylation – requirements for which appear to be different for binding to Frizzled-family and RTK-family Wnt
receptors. We also hope to define specificity determinants in the Wnt proteins for distinct modes of signaling.
In parallel with these pursuits, we will use a structurally-guided approach, combined with chemical biology and
functional analysis of mutated receptors, to explore the mechanism of signaling by pseudokinases in the RTK
superfamily. These studies will have important implications for the 10% of the human kinome thought to be
pseudokinases, and will systematically test the hypothesis that regulated switching of pseudokinase
conformation is required for signaling. Our approaches will also bring new opportunities for therapeutic
targeting of pseudokinases such as PTK7, Ror2, and Ror1, which have been implicated in several diseases.
Together, our studies will provide important fundamental new insight into signaling by a class of receptors that
do not fit into normal paradigms for RTKs or Wnt receptors. Understanding them is crucial for deconvoluting
the complexity of Wnt signaling specificity and teasing out its multiple roles. In addition, our findings should
open new avenues for potential therapeutic inhibition – as the roles of these Wnt-binding RTKs in disease
become increasingly clear.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding how receptor tyrosine kinase activation dynamics specify proliferative cellular responses
-
批准号:10678825
-
项目类别:
-
资助金额:$51.82万
-
财政年份:2020
-
负责人:Mark A Lemmon
-
依托单位:
Project 1: Improved Targeting of EGFR Family Members in Squamous Cell Carcinomas of the Head and Neck
-
批准号:10668978
-
项目类别:
-
资助金额:$35.71万
-
财政年份:2020
-
负责人:Mark A Lemmon
-
依托单位:
Understanding how receptor tyrosine kinase activation dynamics specify proliferative cellular responses
-
批准号:10263909
-
项目类别:
-
资助金额:$52.88万
-
财政年份:2020
-
负责人:Mark A Lemmon
-
依托单位:
Project 1: Improved Targeting of EGFR Family Members in Squamous Cell Carcinomas of the Head and Neck
-
批准号:10441508
-
项目类别:
-
资助金额:$35.43万
-
财政年份:2020
-
负责人:Mark A Lemmon
-
依托单位:
Project 1: Improved Targeting of EGFR Family Members in Squamous Cell Carcinomas of the Head and Neck
-
批准号:10267847
-
项目类别:
-
资助金额:$35.71万
-
财政年份:2020
-
负责人:Mark A Lemmon
-
依托单位:
Understanding how receptor tyrosine kinase activation dynamics specify proliferative cellular responses
-
批准号:10400914
-
项目类别:
-
资助金额:$51.82万
-
财政年份:2020
-
负责人:Mark A Lemmon
-
依托单位:
Understanding Signaling by Non-Canonical Receptor Tyrosine Kinases
-
批准号:10598118
-
项目类别:
-
资助金额:$77.05万
-
财政年份:2017
-
负责人:Mark A Lemmon
-
依托单位:
Understanding Signaling by Non-Canonical Receptor Tyrosine Kinases
-
批准号:9275679
-
项目类别:
-
资助金额:$80.4万
-
财政年份:2017
-
负责人:Mark A Lemmon
-
依托单位:
Understanding Signaling by Non-Canonical Receptor Tyrosine Kinases
-
批准号:10406442
-
项目类别:
-
资助金额:$77.05万
-
财政年份:2017
-
负责人:Mark A Lemmon
-
依托单位:
Understanding Wnt signaling through Ror and Ryk family receptor tyrosine kinases
-
批准号:9244390
-
项目类别:
-
资助金额:$53.21万
-
财政年份:2016
-
负责人:Mark A Lemmon
-
依托单位:
Understanding Wnt signaling through Ror and Ryk family receptor tyrosine kinases
-
批准号:8703139
-
项目类别:
-
资助金额:$55.06万
-
财政年份:2013
-
负责人:Mark A Lemmon
-
依托单位:
Understanding Wnt signaling through Ror and Ryk family receptor tyrosine kinases
-
批准号:8561321
-
项目类别:
-
资助金额:$55.06万
-
财政年份:2013
-
负责人:Mark A Lemmon
-
依托单位:
Signaling by growth factor receptors with intracellular pseudokinase domains
-
批准号:8218293
-
项目类别:
-
资助金额:$43.03万
-
财政年份:2012
-
负责人:Mark A Lemmon
-
依托单位:
Signaling by growth factor receptors with intracellular pseudokinase domains
-
批准号:8774916
-
项目类别:
-
资助金额:$39.92万
-
财政年份:2012
-
负责人:Mark A Lemmon
-
依托单位:
Signaling by growth factor receptors with intracellular pseudokinase domains
-
批准号:8418723
-
项目类别:
-
资助金额:$41.58万
-
财政年份:2012
-
负责人:Mark A Lemmon
-
依托单位:
Signaling by growth factor receptors with intracellular pseudokinase domains
-
批准号:8584298
-
项目类别:
-
资助金额:$39.92万
-
财政年份:2012
-
负责人:Mark A Lemmon
-
依托单位:
STRUCTURAL CHARACTERIZATION OF F-BAR DOMAINS
-
批准号:8361677
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2011
-
负责人:Mark A Lemmon
-
依托单位:
STRUCTURAL STUDIES OF DROSOPHILA ANAPLASTIC LYMPHOMA KINASE
-
批准号:8363573
-
项目类别:
-
资助金额:$0.1万
-
财政年份:2011
-
负责人:Mark A Lemmon
-
依托单位:
ErbB receptor homo- and hetero-dimerization
-
批准号:7809262
-
项目类别:
-
资助金额:$42.76万
-
财政年份:2009
-
负责人:Mark A Lemmon
-
依托单位:
Mechanisms of invertebrate EGF receptor inhibition
-
批准号:7816802
-
项目类别:
-
资助金额:$23.67万
-
财政年份:2007
-
负责人:Mark A Lemmon
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: